INTRODUCTION {#sec1-1}
============

Polycystic ovary syndrome (PCOS) is a heterogeneous, multisystem endocrinopathy in women of reproductive age manifested with various metabolic disturbances and a wide spectrum of clinical features such as obesity, menstrual abnormalities and hyperandrogenism. Current incidence of PCOS (5-6%) in women is related to change in lifestyle and stress \[[@ref1]\].

According to the World Health Organization, it was estimated that 116 million women (3.4%) have PCOS with prevalence ranging from 2.2% to 26% globally \[[@ref2]\]. Hyperinsulinemia was noted in 50% to 70% of PCOS patients and played a central role in the development of further complications. In spite of hyperinsulinemia, there is an increased prevalence of insulin resistance (IR) in PCOS patients which can lead to increased glucose tolerance and type 2 diabetic mellitus (T2DM). Increased insulin leads to increased androgen production from the ovarian thecal cells and this hyperandrogenemia is responsible for androgenic obesity.

The prevalence of obesity in PCOS ranges from 38% to 87%. It was reported that in obese PCOS women, the prevalence of IR was higher than obese women without PCOS in the control group \[[@ref3]\].

MATERIAL AND METHODS {#sec1-2}
====================

The present case control study was conducted in the Department of Biochemistry in collaboration with the Department of Obstetrics and Gynaecology, Pt. B. D. Sharma PGIMS, Rohtak. After getting written consent from the cases and controls, detailed history were obtained and recorded in their respective proforma. They were subjected to physical examination and anthropometric measurements as per protocol followed by systemic examination, urine pregnancy test was done to rule out pregnancy, ultrasonography of abdomen and pelvis were performed in all subjects of this study.

Inclusion criteria {#sec2-1}
------------------

Newly diagnosed cases of PCOS as per Rotterdam definition - the existence of the following three criteria to make the diagnosis of PCOS: oligo-ovulation or anovulation;clinical or biochemical signs of hyper-androgenism; andpolycystic ovaries by Ultrasonography \[[@ref4]\].

Exclusion criteria {#sec2-2}
------------------

Any history suggestive of other potential causes of hyperandrogenism/oligo/amenorrhea \[congenital adrenal hyperplasia, androgen secreting tumor\], hypothyroidism, cushing\'s syndrome, hyperprolactinemia, other pituitary/adrenal disorders, other insulin resistance conditions (acromegaly), history of any drug intake and pregnancy \[[@ref3]\].

Thirty age matched healthy females with regular menstrual cycle and not on any treatment were enrolled as controls.

Anthropometric measurements {#sec2-3}
---------------------------

The weight and standing height of all study subjects were measured twice by using calibrated weighing scale and stadiometer with a fixed vertical backboard and an adjustable head piece respectively by two different examiners to avoid subjective error. BMI is expressed in the units of kg/m2. BMI can be calculated by the present weight in kg divided by square of height in metres (Quetelet index). According to the World Health Organisation, BMI can be graded into the categories listed in [Table 1](#table001){ref-type="table"}.

SAMPLE COLLECTION {#sec1-3}
=================

Six mL of venous blood sample after fasting (10-12 hours) was taken from the antecubital vein aseptically on the second day of menstruation, out of which 2 mL of blood in EDTA anticoagulant vacutainer, 2 mL in sodium fluoride vacutainer and 2 mL in plain vacutainer. Serum from sodium fluoride and plain vacutainer were separated by centrifugation at 2000 rpm for 5 minutes and fasting plasma glucose (FBG) and hormones were determined. EDTA anticoagulant sample was used for hemoglobin and HbA~1c~ determination.

The FBG was performed by enzymatic method (Glucose oxidase method) \[[@ref6]\], HbA~1c~ by latex agglutination inhibition assay \[[@ref7]\] on the RANDOX autoanalyser. Prolactin, total testosterone, luteinising hormone (LH) & follicular stimulating hormone (FSH) were estimated on the Advia Centaur\' CP immunoassay system by chemiluminescence method \[[@ref8]\]. Thyroid stimulating hormone (TSH) was quantitated by immunoradiometric assay by IRMA kit (IRMAK - 9) \[[@ref9]\]. Hemoglobin estimation was done by acid haematin method using Sahli\'s hemoglobinometer \[[@ref10]\].

STATISTICAL ANALYSIS {#sec1-4}
====================

Unpaired \'t\' test and two-tailed Pearson\'s correlation were done between variables of PCOS cases and controls using the IBM SPSS version 20 statistical package. Data were considered to be significant if p \< 0.05 and highly significant with p \< 0.001.

RESULTS AND OBSERVATIONS {#sec1-5}
========================

In the present study, we found that 8 newly diagnosed PCOS cases (26.7%) had history of sudden weight gain. Based on categories of BMI, 16 cases and 7 controls were overweight and obese (≥ 25 kg/m^2^) with statistically significant difference between cases and controls (p=0.002). Thirteen cases were within the normal range of BMI and 1 case was underweight.

We observed that 7 cases (89.2 ± 13.9 mg/dL) and 2 controls (88.5 ± 2.7 mg/dL) had FBG ≥ 100 mg/dL with non significant p value \> 0.05. We found that HbA~1c~ showed statistical significant difference (p=0.002) between cases (mean 6.03 ± 1.03%) and controls (mean 5.35 ± 0.43%) ([Tables 2](#table002){ref-type="table"} & [3](#table003){ref-type="table"}).

We noted from our HbA~1c~ data, 10 cases (33.3%) were in pre diabetic range (5.7-6.4%), 11 cases (36.7%) were in diabetic range (≥ 6.5%) and 9 cases (30%) were in non diabetic range (\< 5.7%) according to ADA criteria ([Figure 1](#fig001){ref-type="fig"}).

We observed the prevalence of T2DM and prediabetes were 13.3% (4 cases) and 6.6% (2 cases) in obese PCOS women, respectively. But the prevalence of T2DM and prediabetes were 10% (3 cases) and 16.6% (5 cases) in overweight PCOS women, respectively.

We found that 7 cases (23.3%) were prediabetes with FG 100-126 mg/dL. But among controls, we noticed only one case (3.3%) had prediabetes ([Figure 2](#fig002){ref-type="fig"}).

TWO-TAILED PEARSON\'S CORRELATION BETWEEN PARAMETERS {#sec1-6}
====================================================

In the present study, it was found that HbA~1c~ had positive correlation with BMI (r=0.439, p=.001) ([Figure 3](#fig003){ref-type="fig"}).

DISCUSSION {#sec1-7}
==========

When the hemoglobin is exposed to plasma glucose, there is a spontaneous non-enzymatic glycation of hemoglobin resulting in HbA~1c~ formation. The rate of formation of HbA~1c~ is directly proportional to the concentration of the glucose in the blood and represents integrated values for the glucose over the preceding 8 to 12 weeks. HbA~1c~ is formed by the condensation of glucose with the N-end of each beta chain to form an unstable schiff base. The schiff base may dissociate or may undergo an amadori rearrangement to form a stable ketomine called as HbA~1c~. It has been established that HbA~1c~ is an index of long term blood glucose concentrations and as a measure of the risk for the development of microvascular complications in patients with diabetes mellitus. The formation of HbA~1c~ is an irreversible process and depends on lifespan of RBC and glucose concentration in the plasma. Severe anemia can show false high HbA~1c~, value as the old red blood cell (RBC) population is higher than non anaemic conditions. In haemolytic anaemia, HbA~1c~ value is falsely low as life span of RBC is less. Therefore, it is mandatory to rule out anaemia in our study to avoid false results \[[@ref11]\].

Lerchbaum et al reported that the prevalence of obesity was 24.8% and overweight was 21.8% among PCOS women \[[@ref12]\]. Gomathi et al found that 54% of the women with PCOS were overweight or obese with respect to WHO classification of BMI grading \[[@ref13]\]. Randeva et al reviewed that excess triglycerides enter into cells and activate proteins kinase C-ε and C-θ, ultimately reducing the glucose uptake. This leads to compensatory hyperinsulinemia which can stimulate excess fat deposition by hypertrophy and hyperplasia of adipose cells in the excess calorie environment. This is further aggravating IR by increasing obesity as a vicious cycle. This abnormal fat accumulation increases IR causing glucose intolerance and T2DM \[[@ref14]\].

The prevalence of obesity in the PCOS population ranges from 38% to 87%. It has been reported that in obese PCOS women, the prevalence of IR was higher than obese women with normal menstrual cycle in the control group \[[@ref3]\].

Medeiros et al concluded from their study, among amazonian PCOS women, that HbA~1c~ was elevated in nearly 40% of PCOS patients and had positive correlation with several anthropometric, metabolic factors and androgen levels \[[@ref15]\].

While evaluating PCOS women, along with FBG estimation, they are needed to have oral glucose tolerance test (OGTT) or HbA~1c~ also to assess their metabolic status and can be categorised as per the American Diabetic Association (ADA) guidelines 2015 by the following any one of the criteria listed in [Table 4](#table004){ref-type="table"}.

As OGTT is time consuming and cumbersome test, HbA~1c~ and FBG have been suggested as screening tools for prediabetes and T2DM. They also recommended HbA~1c~ as the superior screening tool for dysglycemia assessment in PCOS women \[[@ref12]\].

Increased LH leads to increased stromal growth accounts for increased ovarian volume. Increased circulating LH stimulates ovarian thecal cells to produce more androgens leading to hyperandrogenemia in turn leads to increased male pattern (top / apple shaped upper abdomen) of fat accumulation both subcutaneously and around viscera which in turn leads to obesity, increased BMI.

High saturated fat, trans fat diet, less poly unsaturated fatty acid (PUFA) intake, high fructose/sucrose intake, low fat and high carbohydrate diet, sedentary life style, leptin resistance can contribute high triglycerides and VLDL-C level in the circulation which can alter plasma membrane composition resulting in decreased tyrosine acetylphosphorylation of insulin receptor \[[@ref17]\].

Kumar et al also observed higher BMI in women with PCOS than in controls \[[@ref27]\]. The present study observations showed that 14 cases (46%) had increased BMI (≥ 25 Kg/m^2^) and increased HbA~1c~ and 16% of cases had normal BMI with increased HbA~1c~ levels. Among controls who had increased HbA~1c~, we found that 6.7% of them had increased BMI and 3.3% had normal BMI. The prevalence of IR was found to be increased in obese PCOS women than in normally menstruating obese women. IR plays a central role in the pathogenesis of PCOS. Obesity is a co-morbid condition which can increase its risk. Though obesity is more prevalent among PCOS women, about 20-30% of PCOS women are not obese. Hyperinsulinemia causes direct hypothalamic effects which lead to abnormal appetite and gonadotropin secretion resulting in increased LH secretion in PCOS. This increased level of LH causes excessive androgen production in the ovaries \[[@ref3]\].

CONCLUSION {#sec1-8}
==========

In conclusion, BMI is associated with glycemic control in PCOS.
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###### 

WHO classification of BMI grading \[[@ref5]\]

  BMI (kg/m^2^)   Classification
  --------------- -------------------
  \< 18.5         Underweight
  18.5--24.9      Normal weight
  25.0--29.9      Overweight
  30.0--34.9      Class I obesity
  35.0--39.9      Class II obesity
  ≥ 40.0          Class III obesity

###### 

Descriptive data of the study groups

  ------------------------------------------------------------------------------------------------------------------------------
  S. No.   Descriptive data   Cases (n = 30)\   Controls (n = 30)\   \'t\' value   p value
                              Mean ± SD         Mean ± SD                          
  -------- ------------------ ----------------- -------------------- ------------- ---------------------------------------------
  1\.      Age (years)        23.26 ± 5.65      23.6 ± 6.45          -0.213        0.832

  2\.      BMI (kg/m^2^)      26.1 ± 4.2        22.9 ± 3.3           3.245         **0.002**[\*](#tfn001){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------

\* - significant difference

\*\* - highly significant difference

###### 

Analytical data of the study groups

  ----------------------------------------------------------------------------------------------------------------------------
  S.No.   Analytical data   Cases (n = 30)\   Controls (n = 30)\   \'t\' value   p value
                            Mean ± SE         Mean ± SE                          
  ------- ----------------- ----------------- -------------------- ------------- ---------------------------------------------
  1\.     FG (mg/dL)        89.23 ± 2.5       88.47 ± 1.4          0.264         0.792

  2\.     Hb (g/dL)         14.16 ± 3.24      11.5 ± 0.17          0.929         0.357

  3\.     HbA1c (%)         6.03 ± 0.19       5.35 ± 0.08          3.364         **0.002**[\*](#tfn003){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------

\* - significant difference

\*\* - highly significant difference

###### 

The ADA guidelines 2015 for diagnosis of diabetes & prediabetes \[[@ref16]\]

        Criteria for diabetes diagnosis
  ----- -----------------------------------------------------------------------
  1\.   HbA~1c~. ≥ 6.5%
  2\.   FBG ≥ 126 mg/dL (7.0 mmol/L)
  3\.   2-hr plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during OGTT (75g)
  4\.   Random plasma glucose ≥ 200mg/dL (11.1mmol/L)
        **Criteria for prediabetes diagnosis**
  1\.   HbA~1c~, 5.7%-6.4%
  2\.   FBG 100-125 mg/dL (5.6-6.9 mmol/L)
  3\.   2-hr plasma glucose 140-199 mg/dL (7.8-11.0 mmol/L) during OGTT (75g)
